A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III (APOC3) a...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Pollin, Toni I., Damcott, Coleen M., Shen, Haiqing, Ott, Sandra H., Shelton, John, Horenstein, Richard B., Post, Wendy, McLenithan, John C., Bielak, Lawrence F., Peyser, Patricia A., Mitchell, Braxton D., Miller, Michael, O'Connell, Jeffrey R., Shuldiner, Alan R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2008
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2673993/
https://ncbi.nlm.nih.gov/pubmed/19074352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.1161524
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg